- Previous Close
103.12 - Open
102.88 - Bid 101.56 x 800
- Ask 101.89 x 800
- Day's Range
101.53 - 103.00 - 52 Week Range
94.48 - 134.63 - Volume
5,569,888 - Avg. Volume
10,547,258 - Market Cap (intraday)
257.113B - Beta (5Y Monthly) 0.41
- PE Ratio (TTM)
21.26 - EPS (TTM)
4.78 - Earnings Date Feb 4, 2025
- Forward Dividend & Yield 3.24 (3.14%)
- Ex-Dividend Date Dec 16, 2024
- 1y Target Est
130.53
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
www.merck.com70,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MRK
View More
Performance Overview: MRK
Trailing total returns as of 11/29/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRK
View MoreValuation Measures
Market Cap
257.11B
Enterprise Value
280.65B
Trailing P/E
21.71
Forward P/E
11.71
PEG Ratio (5yr expected)
0.07
Price/Sales (ttm)
4.09
Price/Book (mrq)
5.78
Enterprise Value/Revenue
5.18
Enterprise Value/EBITDA
14.78
Financial Highlights
Profitability and Income Statement
Profit Margin
19.23%
Return on Assets (ttm)
10.53%
Return on Equity (ttm)
28.33%
Revenue (ttm)
63.17B
Net Income Avi to Common (ttm)
12.15B
Diluted EPS (ttm)
4.78
Balance Sheet and Cash Flow
Total Cash (mrq)
14.59B
Total Debt/Equity (mrq)
85.57%
Levered Free Cash Flow (ttm)
14.02B
Research Analysis: MRK
View MoreCompany Insights: MRK
MRK does not have Company Insights
Research Reports: MRK
View MoreArgus Quick Note: Weekly Stock List for 11/25/2024: 13Fs (What are the Big Guns Buying?)
Volatility in the stock market during the third quarter gave institutional investors a chance to buy the dips. Taking a look at 13F filings from well-known institutional portfolios, we see that the big guns were busy adding new companies to their portfolios or expanding existing holdings. Buying occurred across a range of sectors. Vickers Stock Research, a subsidiary of Argus Research Group, analyzes insider trading and institutional stock ownership. Form 13-Fs, which institutions must file to report their holdings, are due 45 days after the end of calendar quarters and have come in for 3Q24. We review 13Fs of major institutional investors, including activists, to see what they are buying and to look for trends. Activist investing is now less about generating a short-term return and more about achieving long-term returns through an active management/investor partnerships. Based on data from Vickers, the following is a list of select purchases made in the third quarter by some high-profile money managers, including the Argus Research investment ratings.
Trump’s Nomination of RFK Jr. to Lead HHS a Potential Industry Headwind
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
RatingPrice TargetDiscounted price offers buying opportunity
Merck is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an Animal Health division. MRK shares are included in the S&P 500.
RatingPrice TargetThe major indices are lower at midday. The Russell 2000 is off 1%. The yield
The major indices are lower at midday. The Russell 2000 is off 1%. The yield on the 10-year Treasury note is up 9 bps at 4.40%. Oil is flat at $68 per barrel. Bitcoin is down 1% but still over $86,000.